Abstract
Three cycles of neoadjuvant chemotherapy before cystectomy or radiotherapy did not give the 10% improvement in 3-year survival that was judged to be necessary for introduction into routine use. The chemotherapy regimen was associated with a higher pathological complete-response rate in primary tumours, but there was no clear evidence that it would increase survival.
Keywords
CystectomyMedicineChemotherapyVinblastineTransitional cell carcinomaBladder cancerRadiation therapyCisplatinOncologySurgeryUrologyInternal medicineCancer
Related Publications
European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)
The European Association of Urology (EAU) has released an updated version of the guidelines on non-muscle-invasive bladder cancer (NMIBC). To present the 2021 EAU guidelines on ...
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
This overview presents the updated European Association of Urology (EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). To provide practical evidence-base...
Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial
PURPOSE: Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non–small-cell lung cancer (NSCLC). To determine...
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who h...
Publication Info
- Year
- 1999
- Type
- article
- Volume
- 354
- Issue
- 9178
- Pages
- 533-40
- Citations
- 162
- Access
- Closed
External Links
Citation Metrics
162
OpenAlex
Cite This
(1999).
Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists..
PubMed
, 354
(9178)
, 533-40.